Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

PURPOSE: Single-agent PD-1 blockade exhibits limited efficacy in epithelial ovarian cancer (EOC). We evaluated ipilimumab plus nivolumab compared with nivolumab alone in women with persistent or recurrent EOC. METHODS: Eligibility criteria included measurable disease, 1-3 prior regimens, and platinu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Zamarin, Dmitriy, Burger, Robert A., Sill, Michael W., Powell, Daniel J., Lankes, Heather A., Feldman, Michael D., Zivanovic, Oliver, Gunderson, Camille, Ko, Emily, Mathews, Cara, Sharma, Sudarshan, Hagemann, Andrea R., Khleif, Samir, Aghajanian, Carol
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2020
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7255977/
https://ncbi.nlm.nih.gov/pubmed/32275468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02059
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky